Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 6%

Bulls say

Immunocore Holdings PLC is positioned favorably due to its pipeline of innovative therapies, particularly the successful early commercial execution of its lead product, KIMMTRAK, which has demonstrated a significant survival benefit in patients with metastatic uveal melanoma (mUM). The company is also advancing clinical activities and potential treatments across various therapeutic areas, with notable expectations for positive outcomes in upcoming clinical readouts, specifically for candidates IMC-F106C and IMC-M113V. The developments in HIV treatment and other clinical programs underscore Immunocore's commitment to cutting-edge immunotherapies, reinforcing its status as a leader in the TCR-based immunotherapy landscape.

Bears say

Immunocore Holdings faces a challenging outlook primarily due to anticipated low clinical benefit from future PRAME readouts, leading to significantly reduced probabilities of success for key candidates like IMC-F106C in the treatment of cancers. The company may struggle to develop additional successful clinical candidates outside its established platforms, compounded by concerns about treatment safety, scalability, and accessibility that are crucial for advancing innovative therapies. Furthermore, the complexities involved in addressing HIV, including the virus's ability to evade immune responses and the exhaustion of T cells, raise significant concerns regarding the effectiveness of their treatment candidates, indicating a more precarious financial trajectory.

Immunocore Holdings (IMCR) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 18 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.